The following proteins were quantified using enzyme-linked immunosorbent assay kits: neurofilament light chain (NfL) (Human Diagnostics, Umea, Sweden); CXCL13/BLC/BCA-1, granzyme A, and granulysin (R&D System, MN); chitinase 3 like 1 (MicroVue, Athens, OH); perforin, granzyme B, and granzyme H (Invitrogen–Thermo Fisher Scientific, MA), were used according to the manufacturer's instructions.
Granulysin
Manufactured by R&D Systems
Sourced in Sweden, Japan
Granulysin is a cytotoxic protein produced by cytotoxic T lymphocytes and natural killer cells. It exhibits antimicrobial activity against a variety of pathogens.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using granulysin
1
Quantifying Neuroinflammatory Biomarkers
2
Immunohistochemical Analysis of Merkel Cell Carcinoma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Materials. We used the following antibodies for immunohistochemical staining: mouse monoclonal for human pSTAT5B (Abcam, Tokyo, Japan), CD163 (Novocastra, Milton Keynes, UK), CD206 (LifeSpan BioScience, Seattle, WA, USA); goat polyclonal for human matrix metalloproteinase-12 (MMP12) (R & D Systems, Minneapolis, MN, USA); rabbit polyclonal for human periostin (POSTN; Abcam), interleukin-4 (IL4) (LifeSpan BioScience), CD8 (Dako, Kyoto, Japan), granulysin (R & D Systems), and forkhead box P3 (FOXP3) (Abcam).
Patients, tissue samples and immunohistochemical staining. We collected archival formalin-fixed paraffin-embedded skin specimens from each of 24 patients with primary MCC treated at one of three hospitals in Japan: Tohoku University Hospital, Wakayama Medical University Hospital, or Shiga University of Medical Science Hospital (Table I). All patients provided their informed consent.
We retrospectively divided the MCC cases into four outcome groups: those with spontaneous regression (tumor completely disappeared after biopsy) (25, 26) (excellent outcome); those with no recurrence for at least 3 years (good outcome); those with
Patients, tissue samples and immunohistochemical staining. We collected archival formalin-fixed paraffin-embedded skin specimens from each of 24 patients with primary MCC treated at one of three hospitals in Japan: Tohoku University Hospital, Wakayama Medical University Hospital, or Shiga University of Medical Science Hospital (Table I). All patients provided their informed consent.
We retrospectively divided the MCC cases into four outcome groups: those with spontaneous regression (tumor completely disappeared after biopsy) (25, 26) (excellent outcome); those with no recurrence for at least 3 years (good outcome); those with
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!